Cover Image
市場調查報告書

Reata Pharmaceuticals, Inc.的產品平台分析

Reata Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 219815
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
Back to Top
Reata Pharmaceuticals, Inc.的產品平台分析 Reata Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年06月30日 內容資訊: 英文 41 Pages
簡介

Reata Pharmaceuticals, Inc.是美國的製藥企業,開發針對腎臟,呼吸系統及神經退化性疾病,開發著潛在活化Nrf2轉錄因子的抗氧化發炎調節藥。

本報告提供Reata Pharmaceuticals, Inc. 的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Reata Pharmaceuticals, Inc. 概要

  • 公司概要
  • 主要資訊
  • 企業資料

Reata Pharmaceuticals, Inc. :R&D概要

  • 主要的治療範圍

Reata Pharmaceuticals, Inc. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Reata Pharmaceuticals, Inc. :開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Reata Pharmaceuticals, Inc. :藥物簡介

  • bardoxolone methyl
  • RTA-408
  • RTA-801
  • Small Molecules Activating Nrf2 for Rheumatoid Arthritis
  • Small Molecules to Activate Nrf2 for Duchenne Muscular Dystrophy
  • Small Molecule Activating Nrf2 for Cystic Fibrosis
  • Small Molecules to Activate CFTR for Cystic Fibrosis

Reata Pharmaceuticals, Inc. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Reata Pharmaceuticals, Inc. :最近的開發平台趨勢

Reata Pharmaceuticals, Inc. :暫停中的計劃

Reata Pharmaceuticals, Inc. :開發中止的開發中產品

Reata Pharmaceuticals, Inc. :總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07220CDB

Summary

Global Markets Direct's, 'Reata Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Reata Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Reata Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Reata Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Reata Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Reata Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Reata Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Reata Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Reata Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Reata Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Reata Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Reata Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Reata Pharmaceuticals, Inc. Snapshot
    • Reata Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Reata Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Reata Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Reata Pharmaceuticals, Inc. - Pipeline Products Glance
    • Reata Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Reata Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Reata Pharmaceuticals, Inc. - Drug Profiles
    • RTA-408
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bardoxolone methyl
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RTA-301
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RTA-801
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Parkinson's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate Nrf2 for Duchenne Muscular Dystrophy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate Nrf2 for Rheumatoid Arthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Activate Nrf2 for Cystic Fibrosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate CFTR for Cystic Fibrosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Reata Pharmaceuticals, Inc. - Pipeline Analysis
    • Reata Pharmaceuticals, Inc. - Pipeline Products by Target
    • Reata Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Reata Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Reata Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Reata Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Reata Pharmaceuticals, Inc. - Dormant Projects
  • Reata Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • bardoxolone methyl
  • Reata Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Reata Pharmaceuticals, Inc., Key Information
  • Reata Pharmaceuticals, Inc., Key Facts
  • Reata Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Reata Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Reata Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Reata Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2015
  • Reata Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Reata Pharmaceuticals, Inc. - Phase II, 2015
  • Reata Pharmaceuticals, Inc. - Phase I, 2015
  • Reata Pharmaceuticals, Inc. - Preclinical, 2015
  • Reata Pharmaceuticals, Inc. - Discovery, 2015
  • Reata Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Reata Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Reata Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Reata Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Reata Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Reata Pharmaceuticals, Inc. - Dormant Developmental Projects,2015
  • Reata Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015

List of Figures

  • Reata Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Reata Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Reata Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Reata Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Reata Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Reata Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Reata Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top